Evolent Clinical Guideline 3094 for Ultomiris™ (ravulizumab)

Guideline Number:	Applicable Codes	
Evolent_CG_3094		
"Evolent" refers to Evolent Health LLC and Evolent Specialty Services, Inc. *© 2020 - 2025 Evolent. All rights Reserved.*		
Original Date:	**Last Revised Date:**	**Implementation Date:**
February 2020	May 2025	May 2025

TABLE OF CONTENTS

STATEMENT

Purpose

To define and describe the accepted indications for Ultomiris (ravulizumab) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

Evolent is responsible for processing all medication requests from network ordering providers. Medications not authorized by Evolent may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

INDICATIONS

Continuation requests for a not-approvable medication shall be exempt from this Evolent policy provided

- The member has not experienced disease progression on the requested medication AND
- The requested medication was used within the last year without a lapse of more than 30 days of having an active authorization AND
- Additional medication(s) are not being added to the continuation request.

Atypical Hemolytic Uremic Syndrome (aHUS)

- The member has aHUS and Ultomiris (ravulizumab) is being used in members with evidence of hemolysis (LDH above normal/Haptoglobin below normal/Schistocytes on peripheral blood smear) with or without evidence of impaired renal function (serum creatinine above normal).

Paroxysmal Nocturnal Hemoglobinuria (PNH)

- The member has hemolytic paroxysmal nocturnal hemoglobinuria (PNH) and Ultomiris (ravulizumab) is being used to decrease hemolysis.

CONTRAINDICATIONS/WARNINGS

- Contraindications
  - Initiation in patients with unresolved serious *Neisseria meningitidis* infection.
- US Boxed Warning
  - Serious meningococcal infection
    - Ravulizumab increases the risk of serious and life-threatening infections caused by *Neisseria meningitidis.*

- Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ravulizumab, unless the risks of delaying therapy with ravulizumab outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor.
- Patients receiving ravulizumab are at increased risk for invasive disease caused by N. meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.
- Because of the risk of serious meningococcal infections, ravulizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS.

EXCLUSION CRITERIA

- Ultomiris (ravulizumab) is being used after disease progression with the same regimen or other anti-complement therapies [e.g., Soliris (eculizumab)].
- Disease progression while on Ultomiris (ravulizumab) defined by a lack of response in rise of hemoglobin and continued use of blood transfusions.
- Ultomiris (ravulizumab) is not indicated for the treatment of members with Shiga toxin E. coli-related hemolytic-uremic syndrome (STEC-HUS).
- Dosing exceeds single dose limit of Ultomiris (ravulizumab) 3,000 mg as a loading dose or 3,600 mg as a maintenance dose.
- Investigational use of Ultomiris (ravulizumab) with an off-label indication that is not sufficient in evidence or is not generally accepted by the medical community. Sufficient evidence that is not supported by CMS recognized compendia or acceptable peer reviewed literature is defined as any of the following:
  - Whether the clinical characteristics of the patient and the cancer are adequately represented in the published evidence.
  - Whether the administered chemotherapy/biologic therapy/immune therapy/targeted therapy/other oncologic therapy regimen is adequately represented in the published evidence.
  - Whether the reported study outcomes represent clinically meaningful outcomes experienced by patients. Generally, the definitions of Clinically Meaningful outcomes are those recommended by ASCO, e.g., Hazard Ratio of less than 0.80 and the recommended survival benefit for OS and PFS should be at least 3 months.
  - Whether the experimental design, considering the drugs and conditions under investigation, is appropriate to address the investigative question. (For example, in some clinical studies, it may be unnecessary or not feasible to use randomization, double blind trials, placebos, or crossover).
  - That non-randomized clinical trials with a significant number of subjects may be a basis for supportive clinical evidence for determining accepted uses of drugs.

- That case reports are generally considered uncontrolled and anecdotal information and do not provide adequate supportive clinical evidence for determining accepted uses of drugs.
- That abstracts (including meeting abstracts) without the full article from the approved peer-reviewed journals lack supporting clinical evidence for determining accepted uses of drugs.

CODING AND STANDARDS

Codes

- J1303 - Injection, ravulizumab-cwvz, 10 mg

Applicable Lines of Business

☐	CHIP (Children's Health Insurance Program)
☒	Commercial
☒	Exchange/Marketplace
☒	Medicaid
☐	Medicare Advantage

POLICY HISTORY

Date	Summary
May 2025	• Converted to new Evolent guideline template • This guideline replaces UM ONC_1386 Ultomiris (ravulizumab) • Updated references
May 2024	• Updated NCH verbiage to Evolent

LEGAL AND COMPLIANCE

Guideline Approval

Committee

Reviewed / Approved by Evolent Specialty Clinical Guideline Review Committee

Disclaimer

Evolent Clinical Guidelines do not constitute medical advice. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Evolent uses Clinical Guidelines in accordance with its contractual obligations to provide utilization management. Coverage for services varies for individual members according to the terms of their health care coverage or government program. Individual members' health care coverage may not utilize some Evolent Clinical Guidelines. Evolent clinical guidelines contain guidance that requires prior authorization and service limitations. A list of procedure codes, services or drugs may not be all inclusive and does not imply that a service or drug is a covered or non-covered service or drug. Evolent reserves the right to review and update this Clinical Guideline in its sole discretion. Notice of any changes shall be provided as required by applicable provider agreements and laws or regulations. Members should contact their Plan customer service representative for specific coverage information.

REFERENCES

1. Kulasekararaj AG, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood*. 2019 Feb 7;133(6):540-549. doi: 10.1182/blood-2018-09-876805.
2. Barbour T, et al; 311 Study Group Members. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. *Kidney Int Rep*. 2021 Mar 24;6(6):1603-1613. doi: 10.1016/j.ekir.2021.03.884.
3. Wang Y, et al. A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome. *J Med Econ*. 2020 Dec;23(12):1503-1515. doi: 10.1080/13696998.2020.1831519.
4. Ultomiris prescribing information. Alexion Pharmaceuticals, Inc. Boston, MA 2024.
5. Clinical Pharmacology Elsevier Gold Standard 2025.
6. Micromedex® Healthcare Series: Micromedex Drugdex Ann Arbor, Michigan 2025.
7. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium 2025.
8. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD 2025.
9. Ellis LM, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. *J Clin Oncol*. 2014 Apr 20;32(12):1277-80.
10. Medicare Benefit Policy Manual Chapter 15 Covered Medical and Other Health Services: **https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/bp102c15.pdf**.
11. Current and Resolved Drug Shortages and Discontinuations Reported to the FDA: **http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm**.